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Chicago, Illinois; La Jolla, California; New York, New York; and Pittsburgh, PennsylvaniaBackground: Clinical and histopathologic assessment of pigmented skin lesions remains challenging even
for experts. Differentiated and accurate noninvasive diagnostic modalities are highly desirable.Objective: We sought to provide clinicians with such a tool.Methods: A 2-gene classification method based on LINC00518 and preferentially expressed antigen in
melanoma (PRAME) gene expression was evaluated and validated in 555 pigmented lesions (157 training
and 398 validation samples) obtained noninvasively via adhesive patch biopsy. Results were compared
with standard histopathologic assessment in lesions with a consensus diagnosis among 3 experienced
dermatopathologists.Results: In 398 validation samples (87 melanomas and 311 nonmelanomas), LINC00518 and/or PRAME
detection appropriately differentiated melanoma from nonmelanoma samples with a sensitivity of 91% and
a specificity of 69%. We established LINC00518 and PRAME in both adhesive patch melanoma samples
and underlying formalin fixed paraffin embedded (FFPE) samples of surgically excised primary melanomas
and in melanoma lymph node metastases.Limitations: This technology cannot be used on mucous membranes, palms of hands, and soles of feet.Conclusions: This noninvasive 2-gene pigmented lesion assay classifies pigmented lesions into
melanoma and nonmelanoma groups and may serve as a tool to help with diagnostic challenges that
may be inherently linked to the visual image and pattern recognition approach. ( J Am Acad Dermatol
2017;76:114-20.)
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Gerami et al 115made to invasively biopsy an atypical pigmented
lesion to obtain additional information. The well-
established gold standard of routine dermatopathol-
ogy used on the overwhelming majority of cases
again focuses on structural disorder and image along
with pattern recognition.2 Immunohistochemistry
can provide additional information but does notCAPSULE SUMMARY
d The potential of gene expression analysis
to differentiate pigmented skin lesions is
increasingly recognized.
d LINC00518 and/or preferentially
expressed antigen in melanoma gene
expression differentiates primary
melanomas from nonmelanoma lesions
with a negative predictive value greater
than 99%.
d The described gene expression test is a
novel tool to support clinicians in their
efforts to accurately diagnose primary
cutaneous melanomas.introduce a diagnostic para-
digm shift.3
Numerous studies have
shown that molecular anal-
ysis techniques such as
fluorescence in situ hy-
bridization, comparative
genomic hybridization, and
messenger RNA expression
profiling of surgically ob-
tained specimens can
help predict the behavior
of melanocytic neoplasms
including melanoma beyond
traditional methods.4,5 How-
ever, current molecular tech-
niques depend on tissue
obtained via invasive bi-
opsies. A simpler yet accu-
rate and noninvasive
diagnostic tool to support clinical decisions appears
highly attractive and desired by both health care
providers and patients.
Our earlier work demonstrated feasibility of
noninvasive gene expression analysis for mela-
noma.6,7 The current study on 555pigmented lesions,
including 167 melanomas, sought to demonstrate
and validate that the expression of LINC00518 (LINC)
and preferentially expressed antigen in melanoma
(PRAME) can accurately classify pigmented lesions
using a simple 2-gene detection methodology.
METHODS
Subjects and study design
Participants were 18 years of age or older and had
a clinically suspicious pigmented lesion of at least
4 mm in diameter. Participants were excluded if they
had used topical medications or systemic steroids
within 30 days before the study or had a generalized
skin disorder unrelated to skin cancer. All multi-
center study protocols were approved by a central
institutional review board (Western International
Review Board Copernicus Group, WCG) along
with the institutional review boards at clinical test
sites. A total of 28 sites in the United States, Europe,
and Australia were included. All pigmented skin
lesions suspicious for melanoma were selected by
dermatologists experienced in pigmented lesionmanagement. Cases of obvious nodular melanoma
or cases suspicious for nodular melanoma were not
included. The study includes a training set of
samples for development of the classification
method based on LINC and PRAME gene expression
detection and an independent validation set of
samples for validation of target gene expressionand classification methodol-
ogy (Table I). Additional in-
formation about the sample
sets is provided in
Supplemental Tables I and
II (available at http://www.
jaad.org).
Noninvasive adhesive
patch and conventional
surgical biopsies
Each sample collection
involved a 2-step process, a
noninvasive adhesive patch
biopsy followed by a con-
ventional surgical biopsy of
the same pigmented lesion.
For the adhesive patch bi-
opsy, a class I device skin
biopsy kit (DermTech Inc, LaJolla, CA) was used following the manufacturer’s
instructions. All adhesive patch samples in this study
were frozen and stored at 808C before total RNA
extraction. Conventional surgically biopsied samples
were routinely processed and assessed by a primary
reader and a panel of 3 expert dermatopathologists
who provided a consensus diagnosis to assess the
performance of the 2-gene PLA (pigmented lesion
assay). The experts did not unanimously agree on a
melanoma diagnosis in 11% of cases, which were
excluded from this validation study because no
unequivocal gold standard reference diagnosis
could be established. The expert panel diagnosis
was also compared with the primary reader’s diag-
nosis to assess the sensitivity and specificity of the
primary histopathology assessment.
Gene expression analysis on adhesive patch
biopsied samples
Adhesive patches were macrodissected to sepa-
rate lesional tissue from surrounding normal tissue.
Total RNA was isolated from the recovered lesional
tissue using a modified PicoPure procedure (Life
Technologies, Foster City, CA) and reverse tran-
scribed to complementary DNA using SuperScript
VILO complementary DNA synthesis kits (Thermo
Fisher Scientific, Pittsburgh, PA). The resulting com-
plementary DNA was subsequently used for target
Table I. Dermatopathologic diagnoses of
validation set samples
Training
set
(N = 157)
Validation
set
(N = 398)
Melanomas 80 87
Invasive melanomas 59 53
In situ melanomas 18 19
Invasive/in situ melanomas* 3 15
Nevi 67 253
Conventional nevi 20 48
Dysplastic nevi 41 177
Conventional/dysplastic neviy 6 28
Other nonmelanoma diagnosesz 10 58
The training set (n = 157) set included 37 lesions on extremities, 28
on head and neck, and 92 on the trunk (92 men and 65 women,
age range 18-97 y, median age 48 y, median melanoma thickness
0.55 mm). The validation set (n = 398) included 97 lesions on
extremities, 53 on head and neck, and 248 on the trunk (218 men,
179 women, 1 no gender reported). The age range in the
validation set was 19-97 y (median age 49 y). The median
melanoma thickness in the validation set was 0.45 mm.
*Diagnosed as melanoma by 3 dermatopathologists without full
agreement on the invasive/in situ nature of the sample.
yDiagnosed as nevus by 3 dermatopathologists without full
agreement on presence or absence of dysplasia.
zIncludes seborrheic keratosis, lentigo simplex, basal cell
carcinoma, and fibrosis.
Fig 1. Noninvasive adhesive patch skin biopsy.
Abbreviations used:
LINC: LINC00518
PCR: polymerase chain reaction
PRAME: preferentially expressed antigen in
melanoma
qRT: quantitative real-time
SSM: superficial spreading melanoma
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(qRT)-polymerase chain reaction (PCR) on an
ABI7900 PCR system (Life Technologies). Each qRT-
PCR reaction used 3 pg of total RNA, in duplicate, in
20-L volume on 384-well PCR reaction plates
using predesigned gene-specific TaqMan probe
chemistries (Life Technologies). An averaged cycle
threshold value of the duplicate measurements was
used in the analysis. Gene expressionwas considered
detected if the quantitative polymerase chain reac-
tion yielded an amplification curve and ameasurable
cycle threshold value, or not detected if the reaction
yielded an undetermined cycle threshold value
(amplification curve never above detection
threshold). In addition to the 2 target genes, human
b-actin was used as an internal control.
Gene expression analysis in surgically
biopsied samples and in patient-derived
xenografts
We also analyzed 6 FFPE samples of primary
melanomas underlying the lesional skin harvested
via adhesive patches, 5 melanoma lymph node
metastases, and 6 patient-derived xenografts of
metastatic melanomas8 to assess and correlate
expression of LINC and PRAME. Total RNA was
isolated from the FFPE tissue with PureLink FFPE
total RNA isolation kits (Invitrogen, Carlsbad, CA)
following the manufacturer’s instruction, and used in
gene expression measurements following the qRT-
PCR procedures described above.
Statistical analysis
The genes used in this study were previously
reported as part of a larger classification signature.8
Sensitivity, specificity, negative predictive value,
and area under the curveereceiver operating char-
acteristic curve were calculated using R for the
training, validation, and validation subgroup sets (R
Core Team, 2011). Comparison of LINC and PRAME
gene expression in xenografts was performed using
Excel (Microsoft, Redmond, WA).
RESULTS
The adhesive patch used to noninvasively obtain
skin biopsy samples is shown in Fig 1; it collectsstratum corneum tissue samples containing gene
expression information from the underlying pig-
mented lesion. Of adhesive patch biopsied samples,
86% yielded sufficient amounts of total RNA for gene
expression analysis, leading to a quantity-not-
sufficient rate of 14%.
Two sets of clinical samples (training and valida-
tion sets) were used for this 2-gene PLA validation
study. The training set included 157 samples (80
melanomas and 77 nonmelanomas) and the valida-
tion set included a total of 398 samples (87 mela-
nomas and 311 nonmelanomas). In all, 57
melanomas were superficial spreading melanoma
Fig 2. Receiver operating characteristic curves demon-
strating the PLA’s potential to differentiate primary cuta-
neous melanoma samples from nonmelanoma samples
(primarily atypical nevi) based on LINC00518 and/or
preferentially expressed antigen in melanoma detection.
AUC, Area under the curve.
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maligna melanoma type, and 15 had hybrid features
of SSM and lentigo maligna melanoma. The median
thickness of invasive melanomas for the training set
and the validation set was 0.55 mm and 0.45 mm,
respectively. Over two thirds of all nevi were
considered atypical. Table I shows the concordance
diagnoses rendered by a panel of 3 expert dermato-
pathologists that were used as reference points to
assess test performance. Of samples, 11% were
excluded because of discordant histopathologic
diagnosis.
Area under the curve values for the training set
and the validation set samples were 0.93 and 0.90,
respectively (Fig 2). The 2-gene PLA on training set
samples yielded a sensitivity of 91% and a specificity
of 53% (Table II). In the validation set, the sensitivity
and specificity were 91% and 69%, respectively
(Table III). In the set of 203 serially collected
samples, the sensitivity was 79% and the specificity
80%. Melanoma samples were representative of
cases generally seen in clinical practice and included
invasive SSM, SSM in situ, lentigo malignas, and
others with thin SSM being the largest subgroup
(57%). For melanoma samples in the validation set,
the test sensitivity for invasive melanomas and in situ
melanomas was 94% and 89%, respectively. The
calculated negative predictive value exceeded 99%
(based on 7% prevalence).Although validating the importance of LINC and
PRAME gene expression in adhesive patch biopsy
samples of primary melanomas was a clear focus, we
also sought to establish that our targets are detectable
in FFPE blocks of primary melanomas underlying the
corresponding lesional skin in the same patients.
Table IV provides representative examples of 6
primary melanomas and 6 nevus controls with full
concordance reference consensus diagnoses. Fig 3,
A, demonstrates that patient-derived melanoma
xenografts express LINC and PRAME in a fashion
comparable with primary cutaneous melanoma sam-
ples obtained via adhesive patch biopsies (Fig 3, B).
Similarly, analyses of melanoma lymph node metas-
tases also demonstrated detectable levels of LINC
and PRAME in all 5 cases tested (data not shown).
In addition, we also investigated the test’s perfor-
mance and ability to differentiate primary mela-
nomas form nonmelanoma skin lesions relative to
histopathology. We compared the sensitivity of the
primary pathology read with the consensus diag-
nosis of our 3-person dermatopathology expert
panel using the same comparison used to assess
the test. Using the expert reads as the standard, the
primary reader’s sensitivity was 89% (confidence
interval 81%-94%) and the primary reader’s speci-
ficity was 91% (confidence interval 87%-94%,
P\ .001, kappa 0.78).
DISCUSSION
Distinguishing melanomas from nevi based
purely on noninvasive methods using pattern recog-
nition, including gross assessment, dermoscopic
assessment, or use of computerized pattern recog-
nition tools, can be challenging. Many studies
demonstrate a biopsy ratio of greater than 30 benign
lesions for every 1 melanoma.9 Even computerized
assessment and expert dermoscopic assessment
may only result in a ratio of 8 to 1. This study
demonstrates that gene expression analysis per-
formed on stratum corneum samples collected using
an adhesive patch biopsy can detect melanomas in
the appropriate lesional type with an adequate
sensitivity and specificity to contribute to the current
standard of care and potentially significantly
improve the ratio of benign to malignant lesions.
Although LINC and PRAME are of known impor-
tance in melanoma and other tumor types and prior
studies by this group identified these 2 genes’
transcripts in primary pigmented lesion samples,6,7
this is the first study to our knowledge to
demonstrate a combined use of these 2 genes for
optimized and robust pigmented lesion classification
(ie, the 2-gene PLA). Through microarray studies, we
initially identified 312 genes that were differentially
Table II. Performance of LINC00518 and/or preferentially expressed antigen in melanoma detection in the
training set
Biology
of sample
Pathologically
confirmed
Neither of the
2 genes detected
1 of the 2 genes
(LINC or PRAME) detected
Both LINC and
PRAME detected Detection (95% CI)
Melanoma 80 7 8 65 91%, Sensitivity* (83%-96%)
Nonmelanoma 77 41 25 11 53%, Specificityy (42%-65%)
Total 157
CI, Confidence interval; LINC, LINC00518; PRAME, preferentially expressed antigen in melanoma.
*Number of melanoma samples where one or both LINC and PRAME are detected/total melanoma samples 3100.
yNumber of nonmelanoma samples where none of the LINC and PRAME are detected/total nonmelanoma samples 3100.
Table III. Performance of LINC00518 and/or preferentially expressed antigen in melanoma detection in the
validation set
Biology
of sample
Pathologically
confirmed
Neither of the
2 genes detected
1 of the 2 genes
(LINC or PRAME) detected
Both LINC and
PRAME detected Detection (95% CI)
Melanoma 87 8 13 66 91%, Sensitivity (83%-96%)
Nonmelanoma 311 215 63 33 69%, Specificity (64%-74%)
Total 398
CI, Confidence interval; LINC, LINC00518; PRAME, preferentially expressed antigen in melanoma.
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and nonmelanoma lesions, such as nevi. A 17-gene
classifier able to discriminate between melanoma
and nonmelanoma with a high degree of accuracy
was developed.6 Analyses using custom array and
qRT-PCR technologies indicated that 2-gene subsets
of the original 17-gene classifier could provide a
similar ability to separate melanoma from nonmela-
noma samples with high levels of accuracy. LINC
(Long Intergenic Non-Protein Coding RNA 518) and
CMIP (c-Maf inducing protein) and LINC and PRAME
(preferentially expressed antigen in melanoma)
were the best performing gene pairs driving all
separation. PRAME outperformed CMIP in larger
data sets establishing the current optimized PLA
that no longer requires preamplification steps. Low
quantity-not-sufficient rates of 14% for frozen sam-
ples in this study and 9% for samples from ongoing
clinical efforts where samples are shipped at ambient
temperature by courier and processed without the
need for freezing underscore the robustness of the
approach.
The performance of this 2-gene LINC and PRAME
assay using adhesive patch biopsy samples at a cost
comparable with the histopathology gold standard is
similar to a recently reported more complex algo-
rithmic 23-gene postinvasive biopsy assay (90%
sensitivity, 91% specificity) that also includes
PRAME as a key target gene.5 However, the clinical
use is quite different. The previously mentioned 23-
gene assay is used to assess excised specimens with
histopathologic uncertainty. Although the PLA can
also be used in conjunction with follow-up surgicalhistopathology to provide additional information
about gene expression, many clinicians may choose
to use the PLA on lesions they or the patient did not
want to biopsy and that would have otherwise been
observed and reassessed with serial clinical or
dermoscopic photography at a follow-up visit. The
noninvasive nature of tissue collection with adhesive
patch biopsy not only favors what most patients
prefer, but also offers further advantages for patients
with wound-healing issues related to vascular dis-
ease, diabetes, or advanced age. It also provides
further advantages to patients with lesions in cosmet-
ically sensitive areas or who are anticoagulated and
have a tendency to develop hypertrophic scars.
Because the assay uses only 2 genes for pigmented
lesion classification, cost of analysis and turnaround
time of the assay is greatly reduced, and need for
computer algorithmic data interpretation is avoided.
Although histopathology is the gold standard, it is
associated with considerable interrater variability.
This is well documented in current dermatopathol-
ogy literature. In more extreme cases, diagnostic
discordance as high as 38% between dermatopathol-
ogists was reported.10 Brochez et al2 demonstrated in
a large study involving 20 pathologists that their
overall performance of correctly diagnosing mela-
nomas histopathologically reached a sensitivity of
87%. The results of the PLA assay may be of further
assistance in cases in which there is histologic
uncertainty.2
Other prebiopsy tools that help improve physi-
cian performance and guide decisions of derma-
tology practitioners to biopsy a pigmented lesion
Table IV. Expression of LINC00518 and preferentially expressed antigen in melanoma in corresponding
samples from adhesive patch biopsy specimens (patch samples) and surgically obtained biopsy specimens
(FFPE samples) of the same primary cutaneous melanomas and the same nevi (n = 6 per group)
Sample ID Concordance pathology Sample type LINC expression PRAME expression Test result
8542 Melanoma Patch Detected Detected Positive
FFPE Not detected Detected Positive
8612 Melanoma Patch Detected Not detected Positive
FFPE Detected Not detected Positive
9019 Melanoma Patch Detected Detected Positive
FFPE Detected Detected Positive
9023 Melanoma Patch Detected Detected Positive
FFPE Detected Detected Positive
9025 Melanoma Patch Detected Detected Positive
FFPE Detected Detected Positive
9061 Melanoma Patch Detected Detected Positive
FFPE Detected Detected Positive
8523 Nevus Patch Not detected Not detected Negative
FFPE Detected Detected Positive
8550 Nevus Patch Not detected Not detected Negative
FFPE Not detected Detected Positive
8580 Nevus Patch Not detected Not detected Negative
FFPE Not detected Not detected Negative
8583 Nevus Patch Not detected Not detected Negative
FFPE Not detected Not detected Negative
8601 Nevus Patch Not detected Not detected Negative
FFPE Not detected Not detected Negative
8611 Nevus Patch Not detected Not detected Negative
FFPE Not detected Not detected Negative
LINC, LINC00518; PRAME, preferentially expressed antigen in melanoma.
The reference was established via concordance diagnosis of 3 expert dermatopathologists (100% agreement on the diagnosis).
Fig 3. Comparison of LINC00518 (LINC ), actin B (ACTB) and preferentially expressed antigen
in melanoma (PRAME ) gene expression in patient-derived melanoma xenografts (PDX )
compared with nonmelanoma xenografts (A), and in adhesive patch samples of primary
cutaneous melanomas processed with the PDX samples as controls (B). Ct, Cycle threshold.
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informatic support), imaging devices such as
MelaFind (MELA Sciences, Irvington, NY), and
impedance spectroscopy (Nevisense, Scibase,
Stockholm, Sweden). Clinical decisions, supportedby tools or not, are inherently linked to a trade-off
where most often a higher sensitivity (to minimize
the risk of missing melanomas) is chosen at the cost
of a lower specificity (inevitably linked to a higher
rate of potentially avoidable invasive biopsies).11
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clinical utility. A recent article reports a sensitivity
and specificity of 71% and 59%, respectively, for
dermatology practitioners familiar with the use of
dermoscopy; the sensitivity of the also-reported
decision tree classifier to score dermoscopic images
was 96% and the specificity was at 43%, lower than
the clinician’s specificity.11 A similar study using
computer vision reported a sensitivity of 86% and a
specificity of 52%.12 The impedance spectroscopy
device Nevisense (Scibase) showed a sensitivity of
97% and a specificity of 34%. Nevisense (Scibase)
reads seborrheic keratoses as positive.13 MelaFind
(MELA Sciences) is a multispectral imaging device
approved by the Food and Drug Administration for
the early detection of melanoma that exemplifies the
trade-off mentioned above. MelaFind (MELA
Sciences) has a high sensitivity of 98% but a low
specificity of only about 10%.14 The specificity of
these tools does not solve the problem of excessive
numbers of biopsies seen as part of the current
standard of care.15
In summary, we report that the accurate and
objective detection of LINC and/or PRAME gene
expression without the need for complex algorithms
using a noninvasive adhesive patch biopsy may
facilitate the assessment of pigmented lesions for
melanoma. This technologymay also help overcome
diagnostic limitations inherently linked to visual
image and pattern recognition widely used by
clinicians and dermatopathologists.
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Supplemental Table I. Dermatopathologic
diagnoses of validation set samples
Validation
subgroup A
(N = 195)
Validation
subgroup B
(N = 203)
Melanomas 63 24
Invasive melanomas 42 11
In situ melanomas 8 11
Invasive/in situ melanomas* 13 2
Nevi 113 140
Conventional nevi 29 19
Dysplastic nevi 58 119
Conventional/dysplastic neviy 26 2
Other nonmelanoma diagnosesz 19 39
The validation set was composed of archival samples (validation
subgroup A, n = 195) and serially collected samples (validation
subgroup B, n = 203).
*Diagnosed as melanoma by 3 dermatopathologists without full
agreement on the invasive/in situ nature of the sample.
yDiagnosed as nevus by 3 dermatopathologists without full
agreement on presence or absence of dysplasia.
zIncludes seborrheic keratosis, lentigo simplex, basal cell
carcinoma, and fibrosis.
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Supplemental Table II. Performance of LINC00518 and/or preferentially expressed antigen in melanoma
detection in the validation set groups
Sample
lot
Biology
of sample
Pathologically
confirmed
Neither of the
2 genes detected
1 of the 2 genes
(LINC or PRAME)
detected
Both LINC and
PRAME detected Detection (95% CI)
Archival Melanoma 63 3 8 52 95%, Sensitivity (87%-99%)
Nonmelanoma 132 72 36 24 55%, Specificity (46%-63%)
Total 195
Serial Melanoma 24 5 5 14 79%, Sensitivity (58%-93%)
Nonmelanoma 179 143 27 9 80%, Specificity (73%-85%)
Total 203
CI, Confidence interval; LINC, LINC00518; PRAME, preferentially expressed antigen in melanoma.
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